Patent 7364736B2

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (4)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2003-01-22 · recorded 2003-02-04 · reel 014022/0101 · ASSIGNMENT OF ASSIGNORS INTEREST

    Boyle, William J.; Martin, Francis H.AMGEN INC.

    Correspondent: BROWNING, BRUCE

  2. 2003-01-22 · recorded 2003-02-04 · reel 014022/0106 · ASSIGNMENT OF ASSIGNORS INTEREST

    Davis, C. Geoffrey; Corvalan, Jose R.ABGENIX, INC.

    Correspondent: BROWNING, BRUCE

  3. 2007-11-20 · recorded 2007-12-07 · reel 020616/0229 · MERGER

    ABGENIX, INC.AMGEN FREMONT INC.

    Correspondent: BRINCKERHOFF, LYLE

    Merger

  4. 2022-09-22 · recorded 2022-09-26 · reel 054044/0954 · ASSIGNMENT OF ASSIGNORS INTEREST

    AMGEN FREMONT INC.AMGEN INC.

    Correspondent: ANDRUS, MICHELLE S.

    internal reorg

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • William J. Boyle (Amgen Inc.)
  • Francis H. Martin (Amgen Inc.)
  • Jose R. Corvalan (Abgenix, Inc.)
  • C. Geoffrey Davis (Abgenix, Inc.)

Original assignee

The original assignee named on the issued patent US7364736B2 is Amgen Inc. Amgen Inc. is a multinational biopharmaceutical company that develops, manufactures, and markets human therapeutics. The patent claims antibodies to osteoprotegerin ligand (OPGL), which is the target of Amgen's drug denosumab (marketed as Prolia and Xgeva), used for conditions such as osteoporosis and bone loss in cancer. Amgen Inc. is currently operating.

Assignment timeline

  • 2003-01-22 (executed) / recorded 2003-02-04 — Reel 014022/0101
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: BOYLE, WILLIAM J.; MARTIN, FRANCIS H.
    • Assignee: AMGEN INC.
    • Correspondent: BROWNING, BRUCE; AMGEN INC.; THOUSAND OAKS, CA. This correspondent also appears on reel 014022/0106.
    • Context: Transfer of inventor's interest to employer.
  • 2003-01-22 (executed) / recorded 2003-02-04 — Reel 014022/0106
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: DAVIS, C. GEOFFREY; CORVALAN, JOSE R.
    • Assignee: ABGENIX, INC.
    • Correspondent: BROWNING, BRUCE; AMGEN INC.; THOUSAND OAKS, CA. This correspondent also appears on reel 014022/0101.
    • Context: Transfer of inventor's interest to employer.
  • 2007-11-20 (executed) / recorded 2007-12-07 — Reel 020616/0229
    • Conveyance: MERGER
    • Assignor: ABGENIX, INC.
    • Assignee: AMGEN FREMONT INC.
    • Correspondent: BRINCKERHOFF, LYLE; AMGEN INC.; THOUSAND OAKS, CA
    • Context: Merger of Abgenix, Inc. into Amgen Fremont Inc., consolidating ownership under an Amgen subsidiary.
  • 2022-09-22 (executed) / recorded 2022-09-26 — Reel 054044/0954
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: AMGEN FREMONT INC.
    • Assignee: AMGEN INC.
    • Correspondent: ANDRUS, MICHELLE S.; AMGEN INC.; THOUSAND OAKS, CA
    • Context: Internal corporate reorganization, transferring ownership from subsidiary to parent company.

Timeline diagram

timeline
    title Ownership of US 7364736B2
    2002 : Patent Application Filed
    2003 : Inventors assign to Amgen Inc
         : Inventors assign to Abgenix Inc
    2007 : Abgenix Inc merges into Amgen Fremont
    2008 : Patent Issued to Amgen Inc
    2022 : Amgen Fremont Inc assigns to Amgen Inc

NPE / troll-pattern signals

  1. Shell-entity transfer — not present. All assignees (Amgen Inc, Abgenix Inc, Amgen Fremont Inc) are known operating companies in the biopharmaceutical industry, not shell entities.
  2. Known asserter in the chain — not present. None of the assignees (Amgen Inc, Abgenix Inc, Amgen Fremont Inc) are listed as known NPEs.
  3. Repeat correspondent across the chain — not present. While Bruce Browning appears as correspondent for two early assignments, all correspondents (Bruce Browning, Lyle Brinckerhoff, Michelle S. Andrus) are associated with "AMGEN INC." or "AMGEN INC.; THOUSAND OAKS, CA" across the chain. This indicates internal legal counsel for the operating company rather than a recurring third-party attorney or firm associated with NPE activity.
  4. Cascading transfers — not present. The transfers are spread out over several years (2003, 2007, 2022) and correspond to corporate events (inventor assignment, merger, internal reorganization), not rapid transfers between chained LLCs.
  5. Pre-litigation transfer — not present. The most recent assignment was on 2022-09-22 (recorded 2022-09-26), which is more than six months before the earliest litigation noted by Google Patents (2023).
  6. Bankruptcy fire-sale — not present. There is no indication of Amgen Inc. or its subsidiaries undergoing bankruptcy. Abgenix, Inc. was acquired by Amgen, not liquidated in bankruptcy.
  7. Privateering — not present. The patent remains with the original operating company, Amgen Inc.
  8. Defensive aggregator (anti-NPE) — not present. The patent is currently assigned to Amgen Inc., not a defensive aggregator.

Verdict

Operating-company assertion

All recorded assignments for US7364736B2 demonstrate internal transfers consistent with corporate structure and consolidation within Amgen Inc. and its subsidiaries (Abgenix, Inc. and Amgen Fremont Inc.). Amgen Inc. is a major biopharmaceutical company that develops and markets products, including denosumab, which embodies the claims of the patent, and has been involved in litigation related to this patent family.

USPTO Assignment Center search for US7364736B2

Generated 5/29/2026, 8:46:45 PM